Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05557708 · ClinicalTrials.gov registry record · Early Phase 1
A Safety Study of 212Pb-Pentixather Radioligand Therapy
A Early Phase 1 study, sponsored by Yusuf Menda.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT05557708: Clinical Trial Early Phase 1 study, sponsored by Yusuf Menda.
NCT05557708 is a Early Phase 1 study that has not yet begun recruiting, run by Yusuf Menda. The registered enrollment target is 20 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05557708, a Early Phase 1 study, has not yet begun recruiting, sponsored by Yusuf Menda.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.
Primary Outcome
The recommended phase 2 dose is based on the number of dose limiting toxicities observed post-treatment.
Interventions
- DRUG 212-Lead Pentixather
- DIAGNOSTIC_TEST 203-Lead Pentixather SPECT/CT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-07-01 |
| Est. Completion | 2030-06-30 |
| Phase | Early Phase 1 |
What is known before NCT05557708 opens enrollment
NCT05557708 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 2 interventions - of which 212-Lead Pentixather is the first listed.
NCT05557708 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05557708 about?
NCT05557708 is a clinical study titled "A Safety Study of 212Pb-Pentixather Radioligand Therapy". This is a first-in-human clinical trial evaluating the safety of an alpha-radiation treatment (Lead-212 labelled Pentixather) in patients who have been diagnosed with, and previously treated, for atypical carcinoid lesions of the lung.
What is the current status of trial NCT05557708?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2026-07-01. Estimated completion is 2030-06-30.
What interventions are being tested in trial NCT05557708?
The interventions under investigation include: 212-Lead Pentixather (DRUG), 203-Lead Pentixather SPECT/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05557708?
This trial is sponsored by Yusuf Menda, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05557708's enrollment target sits among peer trials
20 1157th of 2000 higher than 709 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI